WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are approximately $12.7 million. Existing investors, including shareholder Jack W. Schuler, as well as institutional and retail investors participated in the offering.

Read more here:
Yield10 Bioscience Announces Closing of $12.7 Million Public Offering

LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Therapeutics”) entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with its primary product liability insurer, Navigators Specialty Insurance Company and Navigators Insurance Company (“Navigators”).

See the article here:
Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.

Read this article:
Codexis Appoints Dr. Esther Martinborough to its Board of Directors

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

Read more:
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST.

Here is the original post:
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.

Read more from the original source:
Landos Biopharma Announces Pricing of Initial Public Offering

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that its Co-founder and CEO, Jody Aufrichtig will be presenting at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being held tomorrow, February 4, 2021 at 9am EST.

Read more:
Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health"

Pet Industry Veteran Brings Track Record of Success Pet Industry Veteran Brings Track Record of Success

Read more:
Better Choice Company Announces Ryan Wilson Vice President of Marketing

New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models from Pfizer and BioNTech’s mRNA-based vaccine candidates, BNT162b1 and BNT162b2, for the prevention of COVID-19 were published in the journal Nature. Some of these data were initially made available to the public on September 9, 2020 via the online preprint server, bioRxiv. For additional details, please read the previously issued press release.

Read more from the original source:
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

FURTHER UPDATE ON USAMRIID CHALLENGE AND ADDITIONAL EUROPEAN PATENT GRANTED FOR VAXIL’S ANTICANCER ANTIBODY PLATFORM

View post:
Vaxil Appoints a Special Advisor to the Board of Directors

FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta™, Zosano’s investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference.

Continue reading here:
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines

-Technology Licensed from Johns Hopkins University-

Read more:
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

An Emerging Markets Sponsored Commentary

Read the rest here:
Emerging Markets Report: Gas on the Fire

Pivotal IDE Study will evaluate SetPoint’s proprietary bioelectronic device for treatment of Rheumatoid Arthritis Pivotal IDE Study will evalute SetPoint’s propriertary bioelectronic device for treatment of Rheumatoid Arthritis

Continued here:
SetPoint Medical Announces First Patient Enrolled in the RESET-RA Study

TORONTO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that the board of directors (the “Board”) has appointed Lu Galasso and Carlo Sistilli as independent directors to the Board. Mr. Galasso will be appointed to the Strategic Planning Committee and Mr. Sistilli will be appointed to the Audit Committee.

View original post here:
Aleafia Health to Appoint Two New Independent Directors

Basel, 01 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accepting the CE mark by mid-February 2021. In comparison to the existing Roche SARS-CoV-2 Rapid Antigen Test, the SARS-CoV-2 Rapid Antigen Test Nasal collects the sample from the front area of the nose instead of the nasopharynx, resulting in a simplified and faster testing procedure1. This testing method can help reduce overall patient discomfort, particularly in sensitive individuals such as children, elderly people and/or people with disabilities. Besides being less invasive, the test also provides patients with the option to self-collect their nasal sample under the supervision of a healthcare professional. Through reduced physical contact, this method of testing can help to decrease the risk of exposure to the virus for healthcare professionals. Whether the test could also be used without supervision of a healthcare professional will depend on local regulatory requirements. “Rapid testing continues to play an important role in the fight against COVID-19, especially in places when laboratory testing is not available and quick results are needed, such as nursing homes, healthcare facilities, and schools.” said Thomas Schinecker, CEO Roche Diagnostics. “The SARS-CoV-2 Rapid Antigen Test Nasal provides patients with a more comfortable testing experience.” The launch is a partnership with SD Biosensor Inc., with whom Roche has also launched a SARS-CoV-2 Rapid Antibody Test in July and a SARS-CoV-2 Rapid Antigen Test in September 2020. SD Biosensor, is currently preparing to submit an Emergency Use Authorisation (EUA) to the U.S. Food and Drug Administration (FDA). The test is the latest addition to Roche's comprehensive COVID-19 portfolio to support healthcare systems in diagnosing SARS-CoV-2 infection. About the SARS-CoV-2 Rapid Antigen Test Nasal The SARS-CoV-2 Rapid Antigen Test Nasal is a rapid chromatographic immunoassay for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 present in human nasal specimens. In clinical studies, the SARS-CoV-2 Rapid Antigen Test Nasal showed a relative sensitivity of 90.6% (Ct value ? 30; 95 % CI: 75.0 % - 98.0 %) and a specificity of 98.6% for professionally collected samples. For self-collected samples a sensitivity of 84.4 % (Ct value ? 30; 95 % CI: 67.2 % - 94.7 %) and a specificity of 99.2% was detected. Overall the studies contained  468  symptomatic and asymptomatic individuals2. This test is intended to detect antigen from SARS?CoV?2 in individuals suspected of COVID?19 or with known or suspected exposure to SARS?CoV?2. This product is intended for professional use in laboratory and Point of Care environments, and/or self-collection under the close supervision of a healthcare worker. About antigen testing An antigen test detects proteins which are structural or functional components of a pathogen and are thus very specific to that pathogen3. In this case, the test would provide a qualitative “yes/no” answer on the presence of the pathogen in the patient sample and can be offered as a rapid strip test that is performed at the point of care. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies and generate a visually detectable signal on the test strip, typically with results ready in 15 minutes. A rapid antigen test can reliably detect individuals with a high viral load allowing healthcare professionals to quickly identify those patients at greatest risk of spreading the infection.4 About Roche’s response to the COVID-19 pandemicThe COVID-19 pandemic continues to evolve globally with varying developments from country to country and we are partnering with healthcare providers, laboratories, authorities and organisations to help make sure that patients receive the tests, treatment and care they need. This new test is an additional step in Roche’s fight against the COVID-19 pandemic, which has already included:

Read the original post:
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection

NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that it is developing a second clinical candidate, votucalis, which specifically inhibits histamine.

Excerpt from:
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease

Pharmaceutical industry veteran brings more than 20 years of global business development experience across various disease areas Pharmaceutical industry veteran brings more than 20 years of global business development experience across various disease areas

Follow this link:
Cerevance Appoints Carrie Ann Cook As Chief Business Officer

Nicox SASociété anonyme with a registered capital of € 37,030,335

See more here:
Number of voting rights as of January 31, 2021

Press Release

Link:
Immunicum AB (publ) Announces New Interim CFO Lotta Ferm